11.47 USD
+0.26 (+2.32%)
We assign a fundamental rating of 4 out of 10 to VREX. VREX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. VREX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VREX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VREX was profitable.
In the past year VREX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: VREX reported negative net income in multiple years.
Of the past 5 years VREX 4 years had a positive operating cash flow.
1.2 Ratios
VREX has a Return On Assets of -12.34%. This is comparable to the rest of the industry: VREX outperforms 58.51% of its industry peers.
Looking at the Return On Equity, with a value of -29.10%, VREX is in line with its industry, outperforming 56.38% of the companies in the same industry.
VREX's Return On Invested Capital of 5.07% is fine compared to the rest of the industry. VREX outperforms 77.13% of its industry peers.
VREX had an Average Return On Invested Capital over the past 3 years of 5.22%. This is below the industry average of 8.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.34% | ||
| ROE | -29.1% | ||
| ROIC | 5.07% |
ROA(3y)0.83%
ROA(5y)-0.21%
ROE(3y)1.75%
ROE(5y)-0.79%
ROIC(3y)5.22%
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 7.00%, VREX is doing good in the industry, outperforming 72.34% of the companies in the same industry.
VREX's Operating Margin has declined in the last couple of years.
VREX's Gross Margin of 34.06% is on the low side compared to the rest of the industry. VREX is outperformed by 72.87% of its industry peers.
VREX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7% | ||
| PM (TTM) | N/A | ||
| GM | 34.06% |
OM growth 3Y-20.79%
OM growth 5Y-6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.37%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VREX is destroying value.
VREX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VREX has an Altman-Z score of 1.87. This is not the best score and indicates that VREX is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.87, VREX is in line with its industry, outperforming 57.45% of the companies in the same industry.
The Debt to FCF ratio of VREX is 10.24, which is on the high side as it means it would take VREX, 10.24 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 10.24, VREX is doing good in the industry, outperforming 71.81% of the companies in the same industry.
VREX has a Debt/Equity ratio of 0.82. This is a neutral value indicating VREX is somewhat dependend on debt financing.
VREX's Debt to Equity ratio of 0.82 is on the low side compared to the rest of the industry. VREX is outperformed by 71.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.82 | ||
| Debt/FCF | 10.24 | ||
| Altman-Z | 1.87 |
ROIC/WACC0.74
WACC6.83%
2.3 Liquidity
VREX has a Current Ratio of 3.51. This indicates that VREX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.51, VREX is in the better half of the industry, outperforming 63.30% of the companies in the same industry.
A Quick Ratio of 1.82 indicates that VREX should not have too much problems paying its short term obligations.
VREX has a Quick ratio (1.82) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
VREX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.00%, which is quite impressive.
Measured over the past years, VREX shows a very strong growth in Earnings Per Share. The EPS has been growing by 57.78% on average per year.
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.28%
3.2 Future
VREX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.20% yearly.
VREX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.86% yearly.
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 13.03, which indicates a correct valuation of VREX.
VREX's Price/Earnings ratio is rather cheap when compared to the industry. VREX is cheaper than 90.43% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.98. VREX is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 13.99, the valuation of VREX can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VREX indicates a rather cheap valuation: VREX is cheaper than 88.30% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.79. VREX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.03 | ||
| Fwd PE | 13.99 |
4.2 Price Multiples
93.09% of the companies in the same industry are more expensive than VREX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, VREX is valued cheaply inside the industry as 95.21% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.1 | ||
| EV/EBITDA | 9.63 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.23
EPS Next 2Y8.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VREX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:VREX (11/26/2025, 9:45:09 AM)
11.47
+0.26 (+2.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.29%
Inst Owner Change2.62%
Ins Owners1.66%
Ins Owner Change-1.28%
Market Cap478.30M
Revenue(TTM)N/A
Net Income(TTM)-132.50M
Analysts83.64
Price Target18.16 (58.33%)
Short Float %2.13%
Short Ratio3.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)242.7%
Min EPS beat(2)81.21%
Max EPS beat(2)404.2%
EPS beat(4)4
Avg EPS beat(4)171.36%
Min EPS beat(4)81.21%
Max EPS beat(4)404.2%
EPS beat(8)5
Avg EPS beat(8)76.69%
EPS beat(12)9
Avg EPS beat(12)57.27%
EPS beat(16)12
Avg EPS beat(16)50.06%
Revenue beat(2)2
Avg Revenue beat(2)3.04%
Min Revenue beat(2)1.51%
Max Revenue beat(2)4.57%
Revenue beat(4)3
Avg Revenue beat(4)1.03%
Min Revenue beat(4)-3.1%
Max Revenue beat(4)4.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.55%
Revenue beat(12)5
Avg Revenue beat(12)-0.08%
Revenue beat(16)8
Avg Revenue beat(16)-0.01%
PT rev (1m)2.3%
PT rev (3m)2.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.03 | ||
| Fwd PE | 13.99 | ||
| P/S | 0.58 | ||
| P/FCF | 13.1 | ||
| P/OCF | 8 | ||
| P/B | 1.05 | ||
| P/tB | 1.98 | ||
| EV/EBITDA | 9.63 |
EPS(TTM)0.88
EY7.67%
EPS(NY)0.82
Fwd EY7.15%
FCF(TTM)0.88
FCFY7.63%
OCF(TTM)1.43
OCFY12.5%
SpS19.7
BVpS10.92
TBVpS5.8
PEG (NY)N/A
PEG (5Y)0.23
Graham Number14.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.34% | ||
| ROE | -29.1% | ||
| ROCE | 6.41% | ||
| ROIC | 5.07% | ||
| ROICexc | 5.16% | ||
| ROICexgc | 6.81% | ||
| OM | 7% | ||
| PM (TTM) | N/A | ||
| GM | 34.06% | ||
| FCFM | 4.44% |
ROA(3y)0.83%
ROA(5y)-0.21%
ROE(3y)1.75%
ROE(5y)-0.79%
ROIC(3y)5.22%
ROIC(5y)N/A
ROICexc(3y)6.12%
ROICexc(5y)N/A
ROICexgc(3y)9.48%
ROICexgc(5y)N/A
ROCE(3y)6.6%
ROCE(5y)N/A
ROICexgc growth 3Y-22.06%
ROICexgc growth 5Y-8.2%
ROICexc growth 3Y-20.52%
ROICexc growth 5Y-5.73%
OM growth 3Y-20.79%
OM growth 5Y-6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.94%
GM growth 5Y-0.37%
F-Score5
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.82 | ||
| Debt/FCF | 10.24 | ||
| Debt/EBITDA | 4.43 | ||
| Cap/Depr | 87.92% | ||
| Cap/Sales | 2.84% | ||
| Interest Coverage | 1.88 | ||
| Cash Conversion | 71.19% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.51 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | 1.87 |
F-Score5
WACC6.83%
ROIC/WACC0.74
Cap/Depr(3y)70.75%
Cap/Depr(5y)62.44%
Cap/Sales(3y)2.7%
Cap/Sales(5y)2.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.28%
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.37%
EBIT growth 3Y-21.02%
EBIT growth 5Y-6.03%
EBIT Next Year118.8%
EBIT Next 3Y36.54%
EBIT Next 5YN/A
FCF growth 1Y-31.52%
FCF growth 3Y-35.91%
FCF growth 5Y-17.1%
OCF growth 1Y-23.72%
OCF growth 3Y-20.06%
OCF growth 5Y-8.03%
VAREX IMAGING CORP / VREX FAQ
What is the fundamental rating for VREX stock?
ChartMill assigns a fundamental rating of 4 / 10 to VREX.
Can you provide the valuation status for VAREX IMAGING CORP?
ChartMill assigns a valuation rating of 6 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.
What is the profitability of VREX stock?
VAREX IMAGING CORP (VREX) has a profitability rating of 3 / 10.
Can you provide the financial health for VREX stock?
The financial health rating of VAREX IMAGING CORP (VREX) is 4 / 10.
What is the earnings growth outlook for VAREX IMAGING CORP?
The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to decline by -6.84% in the next year.